Praimera Biotech AG

Nicolas is heading the administrative and business functions at Praimera. He is one of the founders of the company and has more than 15 years of experience in the biotechnology industry. Prior to starting Praimera, he co-founded and served as CFO as well as member of the Management Board of Formycon AG, a company which is listed on the German Stock Exchange. In his role as CFO, the business graduate was responsible for the company’s successful capital market positioning and various successful financial and strategic transactions.

Maximilian oversees and leads the scientific activities at Praimera Biotech AG.  He joined Praimera from MorphoSys AG, where he led several analytical groups focused on the characterization of therapeutic antibodies throughout the entire drug life cycle from pre-clinical to commercial stage. He holds a doctoral degree from the Technical University of Munich and brings extensive experience in the field of immunology and the development of therapeutic antibodies.

Olaf is a serial entrepreneur and has been involved in a number of successful company formations. He served as CEO of NanoRepro AG and Paedi Protect AG for many years, both of which he also co-founded. At present, he is CEO of Deutsche Kosmetikwerke AG, a company he also helped to set up. 
Further companies he was involved in founding are Formycon AG, alphazoo AG, Deutsche Reinigungswerke AG and Praimera Biotech AG. He currently holds four supervisory board mandates.

Johannes has worked on basic aspects of antibody structure and biology throughout his career. He holds the chair of biotechnology at the Technical University of Munich. He is also a founder of Praimera Biotech AG. For his discoveries in the context of protein folding in vivo and in vitro he obtained several awards such as the Warburg Medal and the Neurath award. He is a member of the Bavarian and German Academies of Science.

Hristo belongs to the founders of Praimera and joined the supervisory board in 2024. He is a Professor of Biopharmaceutical Technology at the Technical University of Munich. His research focuses on the development and production of novel biotherapeutics. Hristo obtained his doctoral degree at the Ludwig-Maximilian University of Munich. He has received several prestigious awards and distinctions, including an ERC grant.

Hermann has many years of professional experience in investment banking. Among other things, he was jointly responsible for the bond trading activities of Deutsche Bank AG. Since 2008, he has contributed his expertise in various functions in asset management and as member of supervisory boards in biotech and other industries.

Carsten is a seasoned biopharma manager with a strong background in human biology, biopharmacy and immunology. During his more than 30 years in the biopharma industry, he was Scientific Director at Baxter Immunotherapy, GM at Hexal Biotech, and CEO at Formycon AG. He brought several biopharmaceutical products from idea to EU / US launch and won several prestigious awards for his contributions to the biopharmaceutical industry. Carsten is one of the founders of Praimera Biotech AG.

Falk is a global leader in understanding therapeutic antibody activity. His research on understanding the pro- and anti-inflammatory activities of antibodies has transformed the way we think about antibodies and has paved the way for next generation therapeutics. In addition to academic research, he serves as a scientific advisor for many biotech companies which has helped to introduce new therapeutic antibodies for treating cancer and autoimmunity.